Janux Therapeutics, Inc.
NASDAQ:JANXBiotechnology
-$0.25 today
- Market cap
- $630.80M
- Beta
- 2.52
- P/E (TTM)
- -7.6
- EPS (TTM)
- -$1.83
Volume 0.98M
Average 1.02M
JANX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Janux Therapeutics, Inc.NASDAQ: JANX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation dips below year-ago levels
Q1 FY2026 stock-based compensation of $9.27M fell 13.4% year over year, behind the +1.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 2.6% from the prior quarter. Over 3 fiscal years it compounded at +32.7% a year.
Context
- Stock-based compensation amounted to 402.2% of revenue in FY2025, up 90.3 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -13.4% toward the trailing-twelve-month pace of +1.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 40.22M USD
- Year-over-year change
- +21.8%
- 4-year CAGR
- +55.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 40.22M | +21.8% |
| FY2024 | 2024-12-31 | 33.02M | +65.1% |
| FY2023 | 2023-12-31 | 20.01M | +16.3% |
| FY2022 | 2022-12-31 | 17.2M | +149.0% |
| FY2021 | 2021-12-31 | 6.91M | — |
Stock-Based Compensation vs competitors
How JANX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1.8% is the 4th highest of 10, against a peer median of -12.0%.
- Stock-based compensation amounts to 179.5% of revenue for JANX, versus a peer median of 14.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $38.79M USD | +1.8% | +32.7% | 179.5% | |
| LTM Sep 2026 | $37.41M USD | +60.8% | +68.9% | — | |
| LTM Sep 2026 | $36.81M USD | -0.7% | — | 32869.6% | |
| LTM Mar 2026 | $34.28M USD | -12.0% | +8.8% | — | |
| LTM Mar 2026 | $12.55M USD | -55.6% | -11.3% | 8.0% | |
| LTM Mar 2026 | $10.93M USD | +20.5% | +16.2% | — | |
| LTM Mar 2026 | $10.03M USD | -58.5% | -18.9% | 10.1% | |
| LTM Mar 2026 | $9.12M USD | +17.3% | -21.7% | 25.6% | |
| LTM Sep 2026 | $7.7M USD | -87.8% | — | 0.6% | |
| LTM Mar 2026 | €7.38M EUR | -44.8% | — | 19.8% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding JANX) | — | -12.0% | -1.2% | 14.9% | |
Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Depreciation & Amortization | 113K | 841K | 1.96M | 2.06M | 2.03M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.91M | 17.2M | 20.01M | 33.02M | 40.22M |
| Change in Working Capital | 8.84M | 4.28M | (6.55M) | 685K | 6.71M |
| Accounts Receivables | 8M | 0 | 0 | 0 | 0 |
| Inventory | 831K | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.14M | (294K) | 277K | 1.58M | 977K |
| Other Working Capital | (2.13M) | 4.57M | (6.83M) | (899K) | 5.74M |
| Other Non-Cash Items | (169K) | (2.18M) | (7.69M) | (10.59M) | (17.57M) |
| Operating Cash Flow | (16.98M) | (42.92M) | (50.58M) | (43.81M) | (82.24M) |
| Capital Expenditures | (1.48M) | (6.45M) | (1.85M) | (359K) | (1.04M) |
| Acquisitions (Net) | 339.48M | (64.71M) | 0 | 0 | 0 |
| Purchases of Investments | (473.63M) | (294.39M) | (317.34M) | (470.58M) | (705.22M) |
| Sales of Investments | 134.15M | 359.1M | 278M | 212.92M | 405.28M |
| Other Investing Activities | (339.48M) | 64.71M | 0 | 0 | 0 |
| Investing Cash Flow | (340.96M) | 58.27M | (41.19M) | (258.02M) | (300.98M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 204.17M | 500K | 56.53M | 698.27M | 5.29M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (347K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.81M | 0 | 3.02M | 14.97M | 0 |
| Financing Cash Flow | 386.52M | 500K | 59.55M | 713.24M | 4.95M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 28.59M | 15.84M | (32.22M) | 411.4M | (378.27M) |
| Free Cash Flow | (18.46M) | (49.37M) | (52.43M) | (44.17M) | (83.28M) |
Janux Therapeutics, Inc.
NASDAQ:JANX
Intrinsic Alpha fair value
Locked
Current Price
$10.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.